The Pharma Letter16h
FDA and EMA accept filings for higher dose of nusinersen in SMA
The US Food and Drug Administration (FDA) has accepted Biogen’s supplemental New Drug Application (sNDA) and the European ...
The Pharma Letter16h
Oral obesity med fares well in early safety research
Competition in the ever-growing market for obesity treatments continues to mount, with positive early data for Hong Kong’s ...
The Pharma Letter19h
Novo Nordisk teams up with IMMvention Therapeutix on SCD
USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license ...
The Pharma Letter23h
J&J down on currency impact despite strong results
Johnson & Johnson presented its financial results for the last quarter of 2024, the year as a whole, and its guidance for ...
The Pharma Letter18h
Xilio shares tumble after mixed vilastobart data
Xilio Therapeutics reports mixed Phase II results for vilastobart with Tecentriq in colorectal cancer. While showing promise in some subsets with a 27% ORR, efficacy in patients with liver metastases ...
The Pharma Letter16h
Unlock your data’s potential and become your competitor’s competitor
And if you’re not thinking data first too - prioritizing your data quality - you risk falling behind your competition and missing out on valuable opportunities.
The Pharma Letter18h
GlobalData tracks 40 years of innovation in FDA review designations
Regulatory authorities, particularly the US Food and Drug Administration (FDA), have played a crucial role in accelerating and incentivizing the development of innovative treatments through review ...